Literature DB >> 1644109

Comparison of thallium-201 and technetium-99m teboroxime myocardial single photon emission tomography with coronary arteriography.

M Oshima1, M Ishihara, H Sano, S Ohsugi, M Ohno, S Hayase, M Yokota, H Akanabe, K Ito, S Sakuma.   

Abstract

Myocardial single photon emission tomography (SPET) using technetium-99m teboroxime (teboroxime) was studied and the results compared with those of thallium-201(thallium) SPET and coronary arteriography in 19 patients. Resting teboroxime SPET was performed initially. Two hours later, exercise teboroxime SPET was performed. Exercise ergometer tests for both teboroxime and thallium were carried out in a supine position. The levels of exercise achieved for both tests were similar. Agreement for the identification of myocardial segments between thallium SPET and teboroxime SPET was 147/171(86%) (NS). When a significant stenosis was defined as greater than or equal to 75% or greater than or equal to 50%, agreement between two radiopharmaceuticals for the detection of diseased vessels was 89% (NS, k = 0.601) or 88% (NS, k = 0.713), respectively. In only 2/19 cases were inferior and posterior segments (3/171) difficult to interpret in teboroxime SPET due to hepatic activity. Thus, teboroxime SPET with a short data acquisition time resulted in a rapid completion for each study and had a good correlation with thallium SPET.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1644109     DOI: 10.1007/bf00185859

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

1.  Myocardial clearance kinetics of technetium-99m-SQ30217: a marker of regional myocardial blood flow.

Authors:  R E Stewart; M Schwaiger; G D Hutchins; P C Chiao; K P Gallagher; N Nguyen; N A Petry; W L Rogers
Journal:  J Nucl Med       Date:  1990-07       Impact factor: 10.057

Review 2.  Clinical experience with technetium-99m teboroxime, a neutral, lipophilic myocardial perfusion imaging agent.

Authors:  L L Johnson; D W Seldin
Journal:  Am J Cardiol       Date:  1990-10-16       Impact factor: 2.778

3.  Diagnostic value of a new myocardial perfusion agent, teboroxime (SO 30,217), utilizing a rapid planar imaging protocol: preliminary results.

Authors:  R C Hendel; B McSherry; M Karimeddini; J A Leppo
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

4.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

5.  Myocardial perfusion imaging with technetium-99m SQ30217: comparison with thallium-201 and coronary anatomy.

Authors:  D W Seldin; L L Johnson; D K Blood; M J Muschel; K F Smith; R M Wall; P J Cannon
Journal:  J Nucl Med       Date:  1989-03       Impact factor: 10.057

6.  Comparative myocardial extraction of two technetium-labeled BATO derivatives (SQ30217, SQ32014) and thallium.

Authors:  J A Leppo; D J Meerdink
Journal:  J Nucl Med       Date:  1990-01       Impact factor: 10.057

7.  Technetium-99m teboroxime scintigraphy. Clinical experience in patients referred for myocardial perfusion evaluation.

Authors:  L Bontemps; X Geronicola-Trapali; Y Sayegh; O Delmas; R Itti; X André-Fouët
Journal:  Eur J Nucl Med       Date:  1991

8.  Tomographic myocardial perfusion imaging with technetium-99m-teboroxime at rest and after dipyridamole.

Authors:  Q S Li; G Solot; T L Frank; H N Wagner; L C Becker
Journal:  J Nucl Med       Date:  1991-10       Impact factor: 10.057

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.